Tenax Therapeutics, Inc. (TENX) CMO reports stock buys, options holdings
Rhea-AI Filing Summary
Tenax Therapeutics, Inc. director and Chief Medical Officer reported recent open-market purchases of the company’s common stock and detailed his equity holdings. On December 2, 2025, he bought 1,000 shares at a weighted average price of $9.0059, followed by 1,500 shares at $9.0786 on December 3 and 2,500 shares at $9.1992 on December 4.
After these transactions he directly owns 2,766 common shares and has additional indirect holdings of 2,500, 1,194, and 1,194 shares through specified family trusts, for which he disclaims beneficial ownership beyond his pecuniary interest. He also beneficially owns stock options over 157, 63, 119, 500,000, and 625,000 shares at stated exercise prices, with vesting tied to time-based schedules and milestones such as a Phase 3 clinical trial, FDA-related steps, and continued employment.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 2,500 | $9.1992 | $23K |
| Purchase | Common Stock | 1,500 | $9.0786 | $14K |
| Purchase | Common Stock | 1,000 | $9.0059 | $9K |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- This transaction was executed in multiple trades at prices ranging from $8.89 to $9.06. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. This transaction was executed in multiple trades at prices ranging from $8.88 to $9.22. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. This transaction was executed in multiple trades at prices ranging from $9.00 to $9.46. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. The Reporting Person is trustee of the Stuart Rich Revocable Trust DTD 11/18/1996 and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. The Reporting Person is special asset advisor to the Stuart Rich 2022 Irrevocable Trust, a Spousal Lifetime Access Trust (the "Trust"). As such, the Reporting Person has voting and dispositive power over the reported securities held in the Trust, however disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. The Reporting Person is co-trustee of the Andrea Rich 2021 Irrevocable Trust and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. The options vest and become exercisable in four equal installments, with 25% vesting after the start of a Phase 3 clinical trial, 25% vesting after the database lock with respect to the trial, 25% vesting after the opening of an Investigational New Drug Application with the U.S. Food and Drug Administration ("FDA"), and 25% vesting after the approval from the FDA, subject to the Reporting Person's continued employment. The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment. The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment. The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on May 16, 2026, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.
FAQ
What insider stock purchases were reported for Tenax Therapeutics, Inc. (TENX)?
The reporting person, a director and Chief Medical Officer of Tenax Therapeutics, Inc., reported open-market purchases of 1,000, 1,500, and 2,500 common shares on December 2, 3, and 4, 2025 at weighted average prices of $9.0059, $9.0786, and $9.1992, respectively.
How does the reporting person characterize his beneficial ownership of Tenax Therapeutics shares held in trusts?
For each of the three trusts, the reporting person notes his role (trustee or advisor) and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest in those shares.
How do some of the Tenax Therapeutics stock options vest for the reporting person?
One option grant vests in four equal installments tied to milestones: the start of a Phase 3 clinical trial, database lock for the trial, opening of an Investigational New Drug Application with the FDA, and FDA approval, each subject to the reporting person’s continued employment.
What is the reporting person’s role at Tenax Therapeutics, Inc. (TENX)?
The reporting person is both a director and an officer of Tenax Therapeutics, Inc., serving as the company’s Chief Medical Officer, and the Form 4 is filed for one reporting person.